Sponsrat Sponsrat

OssDsign board members, CEO and management purchase shares for 889 KSEK

Members of the board, CEO and management of OssDsign AB (publ) have purchased 58 800 shares in the company for a total value of 889 KSEK.

Uppdaterad 2020-11-12
Publicerad 2020-11-12

CEO Morten Henneveld acquired 17 500 shares in a transaction on November 11th. The shares were purchased at an average price of SEK 14.93 per share. Total shareholdings after the transaction amount to 17 500 shares.

Purchases were also made by members of the OssDsign board:
Simon Cartmell, chairman of the board, acquired 17 500 shares in a transaction on November 12. The shares were purchased at an average price of SEK 15.20 per share. Total shareholdings after the transaction amount to 45 000 shares.

Anders Qvarnström, member of the board, acquired 12 000 shares in a transaction on November 11. The shares were purchased at an average price of SEK 15.09 per share. Total shareholdings after the transaction amount to 23 000 shares.

A total of 11 800 shares have also been purchased by other members of the OssDsign management team during the period November 11 – November 12 at an average price of SEK 15.28 per share.

For further information, please contact:
Morten Henneveld, VD, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Platsannonser